Drugs / Nebicapone
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02772627 | Sep → Dec 2001 | Parkinson disease | Bial - Portela C S.A. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03103399 | Sep 2006 → Sep 2007 | Parkinson disease | Bial - Portela C S.A. | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT03097211 Background | Jul → Oct 2006 | Parkinson disease | Bial - Portela C S.A. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nebicapone | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02772627 ↗ |
| Known as | Nebicapona | ChEMBL registry synonym — accepted as the source's own label CHEMBL160038 ↗ |
| Action | Inhibit | “Catechol O-methyltransferase inhibitor” CHEMBL160038 ↗ |
| Modality | Small molecule | — CHEMBL160038 ↗ |
| Route | Oral | “oral route” NCT02772627 ↗ |
| Target | COMT | “Catechol O-methyltransferase inhibitor” CHEMBL160038 ↗ |